Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givosiran DDI Study in AIP Patients
NCT03505853Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Nov 2018
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of givosiran in acute intermittent porphyria (AIP), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Pharmacokinetics of Cytochrome P450 probe cocktail at Day 36. Started Apr 2018; status: completed.
02
Drugs
givosiran
03
Conditions
acute intermittent porphyria (AIP)
Beyond the preview
Go deeper on NCT03505853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505853.